WADA Prohibited is a recurring topic in our peptide coverage. This hub collects every article tagged WADA Prohibited, newest first, each evidence-graded and tied to real, verifiable sources.
An evidence-graded review of the peptides marketed for athletic recovery — BPC-157, ipamorelin, CJC-1295 and TB-500. The honest 2026 verdict: every one is Grade C or D for recovery as an outcome, none is FDA-approved, and all are WADA-banned at all times.
A clinical, evidence-graded look at the four peptides marketed for anxiety and stress — Selank, N-Acetyl Selank Amidate, Semax and DSIP — separating the single human anxiety trial from preclinical and marketing claims.
An evidence-graded review of the peptides marketed for ankle sprains, ATFL tears and Achilles injury. The honest 2026 verdict: no human RCT exists; the strongest case is preclinical (rat Achilles models), and PRP — not a peptide — has the better human ankle evidence.
A clinical monograph on Thymosin Beta-4 (Tβ4) — the actin-sequestering repair peptide with a real, decades-long human-trial record in ocular, dermal and cardiac repair. Grade B human evidence, no FDA-approved product, and an unsettled 2026 legal status.
A clinical monograph on Ac-SDKP (goralatide/seraspenide), the N-terminal tetrapeptide fragment of thymosin beta-4. Human chemoprotection data (Grade B), preclinical-only anti-fibrosis, and a WADA-prohibited 2026 status.
A clinical monograph on Thymalin — the calf-thymus immune bioregulator from Khavinson's lab. Real human trial data graded B, a single-lineage evidence base, and a non-FDA-approved 2026 status.
A clinical monograph on tesofensine (NS2330) — the triple monoamine reuptake inhibitor sold through gray-market 'peptide' channels for weight loss. Real Phase 2 RCT data, no approval anywhere, and WADA-prohibited in 2026.
A clinical monograph on tesamorelin (Egrifta / EGRIFTA WR) — the FDA-approved GHRH analog with genuine Grade-A human RCT evidence for visceral fat in HIV lipodystrophy, and an unproven non-HIV anti-aging market.
A clinical monograph on CJC-1293 — an abandoned albumin-binding GHRH analog from the ConjuChem program that produced CJC-1295. No dedicated human data exist; the evidence grade is D, and it is explicitly banned by WADA.
A clinical monograph on TB-500 — the synthetic thymosin β4 fragment (Ac-LKKTETQ) marketed for tendon, muscle and tissue repair. Strong preclinical biology, no human efficacy RCT of the fragment, and an unsettled 2026 legal status.
A clinical monograph on survodutide (BI 456906) — the investigational once-weekly GLP-1/glucagon dual agonist. Grade A randomized evidence in obesity and MASH, but not approved anywhere as of mid-2026.
A clinical monograph on SLU-PP-332 — the synthetic pan-ERR agonist sold as an 'exercise mimetic.' It is not a peptide, has zero human trials, and is functionally banned in sport.
A clinical monograph on sermorelin — the GHRH(1-29) growth-hormone secretagogue once FDA-approved for diagnosis and pediatric GH deficiency. Real but modest, mostly pre-2000 human trials; the anti-aging marketing outruns the data.
A clinical monograph on examorelin — the International Nonproprietary Name for hexarelin, a synthetic hexapeptide growth-hormone secretagogue. Small human pharmacodynamic trials (Grade B), never approved, and WADA-prohibited at all times.
A clinical monograph on Semax — the Russian-developed ACTH(4-10) heptapeptide used intranasally for stroke recovery and cognition. Real but single-country human data, graded B, with an unsettled 2026 FDA status.
A clinical monograph on Selank (TP-7) — the Russian tuftsin-analog anxiolytic peptide. Small human anxiety trials, a mostly preclinical mechanism, and an unsettled 2026 US legal status.
A clinical monograph on retatrutide (LY3437943) — Eli Lilly's investigational triple GIP/GLP-1/glucagon agonist with the largest pharmacologic weight loss reported to date, graded A on human Phase 3 RCTs, but FDA-unapproved and WADA-prohibited as of mid-2026.
A clinical monograph on PTD-DBM — the CXXC5-Dishevelled disrupting peptide engineered to reactivate Wnt/β-catenin signaling for hair regrowth. Strong target biology, mouse-only efficacy, and no human trials.
A clinical monograph on Prostamax — the synthetic prostate-tropic tetrapeptide Lys-Glu-Asp-Pro (KEDP) from the Khavinson school. The human prostate evidence belongs to the parent bovine-prostate extract, not the synthetic peptide.
A clinical monograph on Pentadeca Arginate (PDA) — the L-arginine salt of BPC-157 marketed for tendon, gut and wound healing. Zero PDA-specific studies, borrowed preclinical data, and an unsettled 2026 legal status.
WADA Prohibited is a topic our editors cover across the site. This hub aggregates the related, evidence-graded guidance.
This hub updates automatically whenever a new article is tagged WADA Prohibited, so the latest coverage appears first.
Yes. Every article here grades its efficacy claims A-D and cites real, verifiable studies, regulatory documents or trial registries.
The majority of compounds documented here are not approved by the FDA for human use. Approved drugs (e.g. semaglutide, tirzepatide) are noted explicitly and require a licensed prescriber.
Many peptides — including BPC-157 and GHK-Cu in injectable form — are sold strictly "for research use only — not for human consumption." Purity, identity, and dosing of such products are not regulated or guaranteed.
Several compounds are banned in competitive sport under the WADA Prohibited List. Athletes risk sanction regardless of intent or formulation.
Always consult a qualified, licensed healthcare professional before considering any compound. Individual risk depends on your full medical context.
This content is for informational and educational purposes only · No physician–patient relationship is created · Evidence grades reflect published data as of the stated revision and may change.